News in brief

Thermo Fisher Scientific Inc to buy Patheon NV for $7.2bn


Thermo Fisher Scientific Inc has announced its intention to buy Patheon NV in a deal agreed by both firms’ boards.

Thermo confirmed the takeover plan today, just hours after Bloomberg reported the firms were in talks.

Thermo said it will finance the purchase price with debt of $5.2bn and $2bn in equity.

The firm cited Patheon's small and large molecule contract manufacturing capacity, network of production plants and 9,000 staff as the driver for the deal. The Netherlands-headquartered contractor will become part of Thermo Fisher's Laboratory Products and Services Segment.  

DSM, which owns 48.7m shares in Patheon, said the deal is expected to close before the end of the year.

Evercore ISI analyst Ross Muken was positive about the deal, explaining that Patheon “has unique leverage to the high growth pharma bio-processing end market, which Thermo already services on the product side.”

He added that: “Thermo brings unique relationships and market share at major BioPharma and Emerging Pharma which should synergize Patheon’s one stop shop approach.” 

See how the deal will impact Thermo here.

Related News

Image: iStock/designer491

Thermo Fisher: $7.2bn Patheon sits in sweet spot for bioproduction business


Patheon to manufacture amyloidosis antibody treatment for Caelum


Thermo Fisher opens single-use tech testing centre in UK

Source Google maps

Tetraphase hires Patheon to make its synthetic antibiotic eravacycline


Thermo Fisher takes rain check: storm closes clinical packaging site

Patheon launches IPO

Patheon launches IPO


Patheon will list on NYSE today

Patheon plant in Ontario, Canada (source Google maps)

Endo pulls Patheon-made birth control pills in US over potency concerns


Actavis pulls Patheon-made diabetes pills after out-of-spec tests

Image: iStock/yezry

Keryx: Patheon and Norwich sites will ensure supply of iron-based Auryxia

Image: iStock/JRLPhotographer

Patheon well placed if Trump succeeds in bringing manufacturing home, analyst


Patheon spends $26m to up capacity for liquid and freeze-dried drugs

Image: iStock/booblik_uk

Patheon: Biologics seeds to bloom in 2018 as products shift to commercial

Image: iStock/stevanovicigor

Patheon ramping up former Roche site to fulfil demand for Western APIs

Related Products

See more related products